ADMA Biologics Inc $ADMA Shares Sold by Rafferty Asset Management LLC

Key Points

• Rafferty Asset Management LLC has significantly reduced its holdings in ADMA Biologics by 56.5%, selling 289,790 shares and now owning 223,338 shares valued at approximately $4.4 million.
• ADMA Biologics reported a quarterly earnings per share (EPS) of $0.15, surpassing analysts' expectations of $0.14, with a 13.8% increase in revenue compared to the same period last year.
• Institutional investors hold 75.68% of ADMA Biologics' stock, indicating a strong institutional interest in the company.

Rafferty Asset Management LLC decreased its position in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 56.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 223,338 shares of the biotechnology company's stock after selling 289,790 shares during the quarter. Rafferty Asset Management LLC owned 0.09% of ADMA Biologics worth $4,431,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. FORA Capital LLC purchased a new stake in ADMA Biologics in the first quarter valued at approximately $541,000. Freedom Investment Management Inc. purchased a new stake in ADMA Biologics in the first quarter valued at approximately $303,000. MetLife Investment Management LLC raised its position in ADMA Biologics by 714.1% in the first quarter. MetLife Investment Management LLC now owns 1,108,911 shares of the biotechnology company's stock valued at $22,001,000 after purchasing an additional 972,699 shares during the period. Campbell & CO Investment Adviser LLC raised its position in ADMA Biologics by 100.2% in the first quarter. Campbell & CO Investment Adviser LLC now owns 89,844 shares of the biotechnology company's stock valued at $1,783,000 after purchasing an additional 44,957 shares during the period. Finally, Jump Financial LLC raised its position in ADMA Biologics by 1,420.0% in the first quarter. Jump Financial LLC now owns 357,256 shares of the biotechnology company's stock valued at $7,088,000 after purchasing an additional 333,752 shares during the period. Hedge funds and other institutional investors own 75.68% of the company's stock.

ADMA Biologics Stock Down 0.7%

Shares of NASDAQ:ADMA traded down $0.12 during trading on Friday, hitting $17.26. The company's stock had a trading volume of 2,527,726 shares, compared to its average volume of 3,391,207. The business has a 50 day moving average price of $17.76 and a two-hundred day moving average price of $18.93. The company has a market capitalization of $4.12 billion, a PE ratio of 20.07 and a beta of 0.54. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.78 and a current ratio of 5.33. ADMA Biologics Inc has a fifty-two week low of $13.50 and a fifty-two week high of $25.67.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.14 by $0.01. The business had revenue of $121.98 million during the quarter, compared to the consensus estimate of $121.77 million. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The company's quarterly revenue was up 13.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.13 earnings per share. As a group, research analysts expect that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have issued reports on ADMA shares. Wall Street Zen lowered ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. Raymond James Financial boosted their target price on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research report on Thursday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $27.67.

Insider Buying and Selling

In related news, Director Jerrold B. Grossman sold 10,000 shares of the business's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $21.31, for a total transaction of $213,100.00. Following the completion of the transaction, the director owned 478,194 shares in the company, valued at approximately $10,190,314.14. The trade was a 2.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Lawrence P. Guiheen sold 20,000 shares of the business's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $20.96, for a total transaction of $419,200.00. Following the transaction, the director owned 94,830 shares of the company's stock, valued at approximately $1,987,636.80. The trade was a 17.42% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 455,621 shares of company stock worth $9,461,633. Corporate insiders own 3.70% of the company's stock.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.